ESMO® 2026 Highlights: Presenter Vignettes – Roberto Iacovelli

Dr. Roberto Iacovelli

Roberto Iacovelli

MD, PhD

UOC Oncologia Medica

LBA88

PErioperative PEmbrolizumab (P) plus metastasis-directed therapy (MDT) versus MDT alone in patients (pts) with oligometastatic renal cell carcinoma (omRCC): the randomized phase II PE-PE trial.